Open an account

Merck

MRK · NYSE

$148.30+$4.67 (+3.25%)TodayMarket closed ·
Prev close $143.63

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

Employees
75,000
Headquarters
Rahway, New Jersey
Listed
Jan 1, 1941
Sector
Health Care
Industry
Pharmaceuticals
Website
merck.com

MRK key statistics

Market cap
365.88B
Price-earnings ratio
113.99
Dividend yield
2.25%
Average volume
9.34M
Volume
9.92M
Open price
$146.30
High today
$149.36
Low today
$146.12
52 Week high
$156.92
52 Week low
$82.01

Merck (MRK) at a glance

As of Oct 20, 2026, Merck (MRK) shares are priced at $148.30, giving the company a market cap of 365.88B, a price-to-earnings ratio of 113.99 and a dividend yield of 2.25%.

Today the stock has traded between $146.12 and $149.36. The current price is 1.5% above the day's low and 0.7% below its high.

Volume so far is 9.92M shares, in line with the average of 9.34M shares a day.

Over the past year Merck has ranged from $82.01 to $156.92, and now sits 88% of the way up that range.

Merck met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.13 per share against an estimate of -$0.2727.

The average analyst price target is $154.99, 4.5% above the current price, from 21 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

71%of 21 analyst ratings say Buy
  • Buy71.4%
  • Hold28.6%
  • Sell0.0%
Price target · 31 analystsAvg $154.99
Low
$106.05
Now
$148.30
High
$195.30

MRK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 13.0% on average.

  1. Q3 FY24: reported $1.57 per share against an estimate of $1.52
  2. Q4 FY24: reported $1.72 per share against an estimate of $1.63
  3. Q1 FY25: reported $2.22 per share against an estimate of $2.16
  4. Q2 FY25: reported $2.19 per share against an estimate of $2.03
  5. Q3 FY25: reported $2.68 per share against an estimate of $2.37
  6. Q4 FY25: reported $2.09 per share against an estimate of $2.03
  7. Q1 FY26: reported -$1.28 per share against an estimate of -$1.52
  8. Q2 FY26: reported -$0.13 per share against an estimate of -$0.2727

MRK news

  • Vandana Singh

    Merck Discontinues Bacterial Infection Drug in Europe

  • Vandana Singh

    Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push

  • Erica Kollmann

    Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks

  • Vandana Singh

    Why Is BioNTech Stock Falling Tuesday?

  • Press releaseBusiness Wire

    Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors

  • Press releaseBusiness Wire

    Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026

  • Namrata Sen

    Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’

  • Ananya Gairola

    Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'

Similar companies

Companies in the same industry as Merck

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.